PRL and breast carcinoma: We have shown that treatment of breast cancer cells, particularly MDA-MB-231 cells, with PRL appreciably increases phosphorylation of the α subunit of AMPK at Thr172 beyond basal levels, which is linked with the phosphorylation and inactivation of one of its downstream effectors, ACC.